The consequences of pharmaceutical tariffs in the United States.

IF 2.3 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of managed care & specialty pharmacy Pub Date : 2025-06-01 Epub Date: 2025-05-06 DOI:10.18553/jmcp.2025.25090

Sean D Sullivan, Jens Grueger, Aidan P Sullivan, Scott D Ramsey

引用次数: 0

Abstract

The Trump Administration has threatened to impose tariffs on imported branded, generic, and biosimilar pharmaceutical products. Although specific details regarding the exact rates and implementation timeline remain unclear, the administration has indicated that these tariffs will be substantial. Tariffs can create supply chain disruptions, increase costs, limit patient access to essential medications, and negatively impact research and innovation. Rather than punitive tariffs, industrial policy options and collaborative international treaties may better serve US economic and public health interests and lead to a more secure and consistent domestic supply of critical medicines.

查看原文本刊更多论文

美国药品关税的后果。

特朗普政府威胁要对进口的品牌、仿制药和生物仿制药产品征收关税。尽管有关确切税率和实施时间表的具体细节尚不清楚，但政府已表示，这些关税将是实质性的。关税可能造成供应链中断，增加成本，限制患者获得基本药物，并对研究和创新产生负面影响。与惩罚性关税相比，产业政策选择和合作性国际条约可能更好地服务于美国的经济和公共卫生利益，并导致更安全、更一致的国内关键药物供应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of managed care & specialty pharmacy Health Professions-Pharmacy

CiteScore

3.50

自引率

4.80%

发文量

131

期刊介绍： JMCP welcomes research studies conducted outside of the United States that are relevant to our readership. Our audience is primarily concerned with designing policies of formulary coverage, health benefit design, and pharmaceutical programs that are based on evidence from large populations of people. Studies of pharmacist interventions conducted outside the United States that have already been extensively studied within the United States and studies of small sample sizes in non-managed care environments outside of the United States (e.g., hospitals or community pharmacies) are generally of low interest to our readership. However, studies of health outcomes and costs assessed in large populations that provide evidence for formulary coverage, health benefit design, and pharmaceutical programs are of high interest to JMCP’s readership.